Technical Data
G8975-23A
GRO beta, Recombinant, Human (CXCL2, MIP-2, Macrophage Inflammatory Protein 2)
2ug
10ug
10ug
|
Technical Data |
|
G8975-23A |
GRO beta, Recombinant, Human (CXCL2, MIP-2, Macrophage Inflammatory Protein 2) |
2ug 10ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
Recombinant Human GRO-beta is a single,non-glycosylated, polypeptide chain containing 73 amino acids and having a molecular mass of 7908 Dalton. Human GRO-beta is purified by proprietary chromatographic techniques. Sequence : The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Pro-Leu-Ala-Thr. Dimers and Aggregates: 1% as determined by silver-stained SDS-PAGE gel analysis. Biological Activity: GRO-beta is fully biologically active when compared to standard. The Biological activity is calculated by its ability to chemoattract CXCR2 transfected 293 cells using 10.0-100.0ng/ml. Endotoxin: 0.1ng/ug (IEU/ug) of Human GRO-beta. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm. 2. Analysis by RP-HPLC, using a calibrated solution of Human GRO-beta as a Reference Standard. Reconstitution: Reconstitute the lyophilized Human GRO-beta in sterile 18MO-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions. Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: E. coli Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Form: Supplied as a lyophilized powder. No additives. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Modulation of the neurotransmitter release in rat cerebellar neurons by GRO beta. Ragozzino D, Giovannelli A, Limatola C, Neuroreport 1998 Nov 16;9(16):3601-6 2. gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. Cao Y, Chen C, Tsang M, J Exp Med 1995 Dec 1;182(6):2069-77 3. Expression of active human GRO beta and GRO gamma neutrophil chemotactic proteins in E. coli. Zagorski J, DeLarco JE, Protein Expr Purif 1994 Aug;5(4):337-45 4. Differential expression of the small inducible cytokines GRO alpha and GRO beta by synovial fibroblasts in chronic arthritis: possible role in growth regulation. Hogan M, Sherry B, Fabre M, Cytokine 1994 Jan;6(1):61-9 5. Interleukin-1-inducible expression of gro-beta via NF-kappa B activation is dependent upon tyrosine kinase signaling. Joshi-Barve SS, Rangnekar VV, Rangnekar VM, J Biol Chem 1993 Aug 25;268(24):18018-29 6. The interleukin-8-related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human neutrophil and basophil leukocytes. Geiser T, Dewald B, Clark-Lewis I, J Biol Chem 1993 Jul 25;268(21):15419-24.
|
||